Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 9:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pulmonary Disorders Clear all
Terminated Phase 2 Interventional Results available

ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy

NCT04372927
View directory record Official record
Conditions
Locally Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8
Interventions
Cisplatin, Durvalumab, Etoposide, Hypofractionated Radiation Therapy, Pemetrexed
Drug · Biological · Radiation
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Sep 18, 2026, 9:40 PM EDT
Recruiting Phase 1 Interventional

Ex Vivo-Expanded Regulatory T Cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic GVHD

NCT06991361
View directory record Official record
Conditions
Graft Versus Host Disease (cGvHD)
Interventions
EVE-Treg
Biological
Lead sponsor
Leslie Kean
Other
Eligibility
2 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 18, 2026, 9:40 PM EDT
Terminated Not applicable Interventional

S0229, Pulmonary Rehabilitation Education w/wo Exercise Training in Improving Physical Function in Patients Who Are Undergoing Chemo & RT for Locally Advanced Lung Cancer

NCT00090961
View directory record Official record
Conditions
Lung Cancer, Pulmonary Complications
Interventions
educational intervention, supervised exercise program
Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
60
States / cities
Fort Collins, Colorado • Decatur, Illinois • Maywood, Illinois + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Sep 18, 2026, 9:40 PM EDT
Completed Phase 3 Interventional

New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia)

NCT00035269
View directory record Official record
Conditions
Pneumonia, Pneumococcal, Community Acquired Infections, Gram-positive Bacterial Infections
Interventions
Antibiotic
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
34
States / cities
Los Angeles, California • Jacksonville, Florida • Naples, Florida + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2011 · Synced Sep 18, 2026, 9:40 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Optimizing and Standardizing 129Xe Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease

NCT04855305
View directory record Official record
Conditions
Interstitial Lung Diseases
Interventions
Hyperpolarized 129Xe
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 18, 2026, 9:40 PM EDT
Completed Phase 4 Interventional

Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Community Acquired Pneumonia (CABP)

NCT01669980
View directory record Official record
Conditions
Infections, Pneumonia
Interventions
Ceftaroline fosamil, IV Ceftriaxone and Vancomycin
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
2 Months to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Long Beach, California • Oakland, California • Orange County, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2015 · Synced Sep 18, 2026, 9:40 PM EDT
Withdrawn Phase 2 Interventional

BIO-11006 for Osteosarcoma and Ewing's Sarcoma Lung Metastases

NCT04183062
View directory record Official record
Conditions
Osteosarcoma Metastatic, Ewing's Sarcoma Metastatic
Interventions
Chemotherapy (gemcitabine & docetaxel) plus BIO-11006
Drug
Lead sponsor
Nicklaus Children's Hospital f/k/a Miami Children's Hospital
Other
Eligibility
5 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Sep 18, 2026, 9:40 PM EDT
Recruiting Phase 1 Interventional

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

NCT05005403
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Micro Satellite Stable Colorectal Cancer, Gastric/Esophageal Cancer, High-Grade Serous Ovarian Cancer, Pancreatic Cancer, Triple Negative Breast Cancer
Interventions
Azirkitug, Budigalimab, Bevacizumab, Telisotuzumab Adizutecan
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
694 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
20
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 18, 2026, 9:40 PM EDT
Completed Phase 1 Interventional

Bronchoscopic Thermal Vapor Ablation (BTVA) for Lung Volume Reduction

NCT01041586
View directory record Official record
Conditions
Emphysema, Chronic Obstructive Pulmonary Disease
Interventions
BTVA System
Device
Lead sponsor
Uptake Medical Corp
Industry
Eligibility
40 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
4
States / cities
Phoenix, Arizona • Iowa City, Iowa • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Sep 18, 2026, 9:40 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Prospective Study of Intensity-Modulated Proton Therapy (IMPT) for Small Cell Lung Cancer

NCT04342429
View directory record Official record
Conditions
Small-cell Lung Cancer
Interventions
Proton-beam Therapy for Small Cell Lung Cancer
Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 18, 2026, 9:40 PM EDT
Terminated Phase 2 Interventional Results available

Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC

NCT04926831
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
capmatinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
La Jolla, California • Sacramento, California • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 18, 2026, 9:40 PM EDT
Completed Not applicable Interventional Results available

Aerosolized Albuterol Use in Severe BPD

NCT02766673
View directory record Official record
Conditions
Severe Bronchopulmonary Dysplasia
Interventions
Albuterol Sulfate, Sterile Saline
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 1 Year
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 18, 2026, 9:40 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Monitoring Health Care Workers at Risk for COVID-19 Using Wearable Sensors and Smartphone Technology

NCT04756869
View directory record Official record
Conditions
Covid19
Interventions
COVID-19 Monitoring Using Wearable Sensors and Smartphone Technology
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Sep 18, 2026, 9:40 PM EDT
Completed Phase 1 Interventional

Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors

NCT00014456
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Carcinoma of Unknown Primary, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma
Interventions
filgrastim, docetaxel, gemcitabine hydrochloride
Biological · Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 27, 2013 · Synced Sep 18, 2026, 9:40 PM EDT
Completed Phase 1Phase 2 Interventional

Oral Taxane in Combination With Pemetrexed (Alimta) in Patients With Recurrent Non-Small Cell Lung Cancer

NCT00103831
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Oral Taxane
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Denver, Colorado • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 1, 2010 · Synced Sep 18, 2026, 9:40 PM EDT
Completed Not applicable Interventional

Comparing Pulmonary Vein Isolation to Pulmonary Vein Isolation + OPTIMA Ablation in Patients Undergoing Ablation for Atrial Fibrillation

NCT04101539
View directory record Official record
Conditions
Atrial Fibrillation Chronic
Interventions
OPTIMA-guided catheter ablation, Standard PVI
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Sep 18, 2026, 9:40 PM EDT
Recruiting Not applicable Interventional

Optimization of Saturation Targets And Resuscitation Trial (OptiSTART)

NCT05849077
View directory record Official record
Conditions
Premature Infants, Bronchopulmonary Dysplasia, Intraventricular Hemorrhage, Neurodevelopmental Outcomes
Interventions
Sat75, Sat50
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
0 Minutes to 10 Minutes
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Sep 18, 2026, 9:40 PM EDT
Completed Phase 3 Interventional Results available

AMPLIFY - D6571C00001 Duaklir USA Phase III Study

NCT02796677
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg), Aclidinium bromide 400 μg (AB 400 μg), Formoterol fumarate 12 μg (FF 12 μg), Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg, Tiotropium 18 μg (TIO 18 μg), Placebo to TIO 18 μg
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
1,595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
85
States / cities
Gulf Shores, Alabama • Phoenix, Arizona • Tucson, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2018 · Synced Sep 18, 2026, 9:40 PM EDT
Completed Phase 3 Interventional Results available

Adaptive COVID-19 Treatment Trial 3 (ACTT-3)

NCT04492475
View directory record Official record
Conditions
COVID-19
Interventions
Interferon beta-1a, Placebo, Remdesivir
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
969 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
55
States / cities
Birmingham, Alabama • Fresno, California • La Jolla, California + 45 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2022 · Synced Sep 18, 2026, 9:40 PM EDT
Recruiting Phase 4 Interventional

Individualizing Treatment for Asthma in Primary Care (Full Study)

NCT07052942
View directory record Official record
Conditions
Asthma, Asthma Attack, Asthma Exacerbations
Interventions
Inhaled corticosteroid (ICS), Azithromycin, Asthma Symptom Monitoring Web-based Application
Drug · Other
Lead sponsor
DARTNet Institute
Government
Eligibility
13 Years to 75 Years
Enrollment
3,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
13
States / cities
Aurora, Colorado • Orlando, Florida • Kansas City, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 18, 2026, 9:40 PM EDT
Recruiting Phase 1 Interventional

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

NCT06835569
View directory record Official record
Conditions
Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC (Non-small Cell Lung Cancer), CRC (Colorectal Cancer), Advanced Solid Tumors
Interventions
ALTA3263, cetuximab, mFOLFOX6, Pembrolizumab, Pemetrexed + Cisplatin /Carboplatin, mFOLFIRINOX, GnP, Midazolam
Drug
Lead sponsor
Alterome Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
12
States / cities
Orlando, Florida • Boston, Massachusetts • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 18, 2026, 9:40 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension

NCT00477269
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Imatinib mesylate, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
3
States / cities
Los Angeles, California • Newark, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 22, 2015 · Synced Sep 18, 2026, 9:40 PM EDT
Completed Not applicable Interventional

Utility of Anatometabolic Imaging for Radiation Treatment Planning for Lung Cancer

NCT00005666
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
PET scan use in radiotherapy planning
Procedure
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 18, 2026, 9:40 PM EDT
Completed Not applicable Interventional

Effects of Innovative Aerobic Exercise Training in Cystic Fibrosis

NCT04543929
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
exercise
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Sep 18, 2026, 9:40 PM EDT